BCAL Diagnostics

BCAL Diagnostics Gross Margin

Gross Margin of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026.

Gross Margin

0.00

Last updated:

Gross Margin of BCAL Diagnostics is 2025 0.00 . Gross Margin of BCAL Diagnostics was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

On Eulerpool you can find the complete historical development of Gross Margin BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's BCAL Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BCAL Diagnostics

All Key Metrics — BCAL Diagnostics